Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ceva Santé Animale maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio has 1 pending office action, which represents the total active prosecution volume for the company. This 1 pending office action is assigned to KASSA, TIGABU, who is the busiest examiner for this entity. Because KASSA, TIGABU holds 1 busiest examiner pending action, the company's immediate success in the Biotechnology & Pharmaceuticals sector relies on this point of contact.
The data reveals a centralized prosecution strategy, with 1 distinct examiner and 1 distinct art unit managing the filings. This lack of variance indicates that the company is likely pursuing a specific technological solution rather than a diverse array of pharmaceutical innovations. With 1 distinct art unit involved, the prosecution experience is subject to the specific internal policies and timelines of that single unit. The presence of 1 distinct examiner simplifies the management of the portfolio, as there is no need to navigate different examiner styles. This 1 pending office action represents a critical juncture for the company's intellectual property assets in the current examination cycle.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793324 | VETERINARY ANTI-PROLACTIN COMPOSITION FOR RUMINANTS USED BY INTRAMAMMARY ADMINISTRATION | KASSA, TIGABU | 59d overdue |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17793324 | VETERINARY ANTI-PROLACTIN COMPOSITION FOR RUMINANTS USED BY INTRAMAMMARY ADMINISTRATION | KASSA, TIGABU | 1619 | §103 | Non-Final OA | 59d overdue | Pending | Jul 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial